ImmuCell Corporation (ICCC) |
5.14 0.04 (0.78%) 04-26 16:00 |
Open: | 5.1 |
High: | 5.14 |
Low: | 5.1 |
Volume: | 1,776 |
Market Cap: | 40(M) |
PE Ratio: | -6.85 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 6.35 |
Resistance 1: | 5.44 |
Pivot price: | 5.11 |
Support 1: | 5.06 |
Support 2: | 4.82 |
52w High: | 6.05 |
52w Low: | 4.26 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
EPS | -0.750 |
Book Value | 3.220 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -33.05 |
Operating Margin (%) | -9.35 |
Return on Assets (ttm) | -7.4 |
Return on Equity (ttm) | -20.9 |
Fri, 26 Apr 2024
ImmuCell's (NASDAQ:ICCC) investors will be pleased with their respectable 35% return over the last five years - Yahoo Movies Canada
Fri, 12 Apr 2024
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average of $5.03 - Defense World
Fri, 12 Apr 2024
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average of $5.03 - Defense World
Tue, 09 Apr 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - Investing.com India
Tue, 09 Apr 2024
ImmuCell reports preliminary Q1 sales, stock climbs 7% (NASDAQ:ICCC) - Seeking Alpha
Thu, 04 Apr 2024
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200 Day Moving Average of $5.03 - Defense World
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |